UA72890C2 - A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition - Google Patents

A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition

Info

Publication number
UA72890C2
UA72890C2 UA2001010591A UA2001010591A UA72890C2 UA 72890 C2 UA72890 C2 UA 72890C2 UA 2001010591 A UA2001010591 A UA 2001010591A UA 2001010591 A UA2001010591 A UA 2001010591A UA 72890 C2 UA72890 C2 UA 72890C2
Authority
UA
Ukraine
Prior art keywords
variants
osanetant
preparation
pharmaceutical composition
crystalline form
Prior art date
Application number
UA2001010591A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UA72890C2 publication Critical patent/UA72890C2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA2001010591A 1998-08-05 1999-08-03 A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition UA72890C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810107A FR2782082B3 (fr) 1998-08-05 1998-08-05 Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
PCT/FR1999/001914 WO2000007987A1 (fr) 1998-08-05 1999-08-03 Formes cristallines du osanetant

Publications (1)

Publication Number Publication Date
UA72890C2 true UA72890C2 (en) 2005-05-16

Family

ID=9529458

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001010591A UA72890C2 (en) 1998-08-05 1999-08-03 A crystalline form of osanetant (variants), a method for the preparation thereof (variants) and a pharmaceutical composition

Country Status (31)

Country Link
US (1) US7041679B2 (de)
EP (1) EP1102747B1 (de)
JP (1) JP3807938B2 (de)
KR (1) KR100571944B1 (de)
CN (1) CN1114592C (de)
AR (1) AR019953A1 (de)
AT (1) ATE243197T1 (de)
AU (1) AU748177B2 (de)
BR (1) BR9913357A (de)
CA (1) CA2339007A1 (de)
CO (1) CO5070576A1 (de)
DE (1) DE69908951T2 (de)
DK (1) DK1102747T3 (de)
DZ (1) DZ3074A1 (de)
EA (1) EA003205B1 (de)
EE (1) EE04274B1 (de)
ES (1) ES2200535T3 (de)
FR (1) FR2782082B3 (de)
HU (1) HUP0103134A3 (de)
IS (1) IS5821A (de)
MY (1) MY121447A (de)
NO (1) NO320645B1 (de)
NZ (1) NZ509561A (de)
PL (1) PL345999A1 (de)
PT (1) PT1102747E (de)
SK (1) SK1742001A3 (de)
TR (1) TR200100261T2 (de)
TW (1) TW527354B (de)
UA (1) UA72890C2 (de)
WO (1) WO2000007987A1 (de)
YU (1) YU8601A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2023278843A2 (en) * 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
JP2000515534A (ja) * 1996-08-05 2000-11-21 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ 3,3―二置換ピペリジンの製造方法
US6040316A (en) * 1996-09-16 2000-03-21 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
HUP0103134A3 (en) 2003-03-28
US7041679B2 (en) 2006-05-09
CN1314888A (zh) 2001-09-26
US20040044215A1 (en) 2004-03-04
TR200100261T2 (tr) 2001-06-21
KR20010072220A (ko) 2001-07-31
MY121447A (en) 2006-01-28
TW527354B (en) 2003-04-11
PT1102747E (pt) 2003-09-30
NZ509561A (en) 2002-10-25
IS5821A (is) 2001-01-23
DE69908951T2 (de) 2004-05-19
ES2200535T3 (es) 2004-03-01
KR100571944B1 (ko) 2006-04-18
AU5168599A (en) 2000-02-28
DE69908951D1 (de) 2003-07-24
AR019953A1 (es) 2002-03-27
CN1114592C (zh) 2003-07-16
FR2782082A1 (fr) 2000-02-11
HK1035535A1 (en) 2001-11-30
SK1742001A3 (en) 2001-11-06
EA003205B1 (ru) 2003-02-27
JP3807938B2 (ja) 2006-08-09
CA2339007A1 (en) 2000-02-17
DZ3074A1 (fr) 2004-07-20
EP1102747A1 (de) 2001-05-30
DK1102747T3 (da) 2003-09-29
JP2002522419A (ja) 2002-07-23
FR2782082B3 (fr) 2000-09-22
NO320645B1 (no) 2006-01-09
NO20010553D0 (no) 2001-02-01
CO5070576A1 (es) 2001-08-28
EE200100070A (et) 2002-06-17
EE04274B1 (et) 2004-04-15
WO2000007987A1 (fr) 2000-02-17
HUP0103134A2 (en) 2002-06-29
EP1102747B1 (de) 2003-06-18
BR9913357A (pt) 2001-05-15
PL345999A1 (en) 2002-01-14
ATE243197T1 (de) 2003-07-15
NO20010553L (no) 2001-04-05
EA200100096A1 (ru) 2001-08-27
AU748177B2 (en) 2002-05-30
YU8601A (sh) 2003-07-07

Similar Documents

Publication Publication Date Title
HUP9701281A2 (en) Piperidine derivatives as neurokinin antagonists and pharmaceutical compositions containing them
HUT76476A (en) Morpholine and thiomorpholine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
EP0747357A3 (de) Dihydropyridine als NPY-Antagonisten: Piperidinderivate
DE69904302D1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
MX9703025A (es) Proceso para preparar levobupivacaina y sus analogos.
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
HUP0900417A3 (en) Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them
CA2263167A1 (en) Ether muscarinic antagonists
YU8601A (sh) Kristalni oblici osanetanta
PT1513528E (pt) Composição farmacêutica contendo forma amorfa estabilizada de cloridrato de donepezilo
HUT63384A (en) Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
IL128561A0 (en) Stable non-hygroscopic crystalline form of N-(N-N-(4-(piperidin-4-YL)butanoyl)-N-ethylglycyl) compounds
SI2157083T1 (sl) Farmacevtske sestave, vsebujoče kristalno obliko (i) lerkanidipin hidroklorida
UA27719C2 (uk) Ефіри 2,6-диметил-1,4-дигідропіридин-3-карбонової кислоти, що є блокаторами кальцієвих каналів, спосіб їх одержання та фармацевтична композиція
EA200000412A1 (ru) Комбинация активных ингредиентов, в частности тетрагидропиридинов и агентов, ингибирующих ацетилхолинэстеразу, для лечения старческой деменции по типу альцгеймера
MX9708612A (es) Derivados de alfa-(alquilfenilo sustituido)-4-(hidroxidifenilmetil)-1-piperidinbutanol, su preparacion y su uso como antihistaminas, agentes antialergicos, y broncodilatadores.
HUP0401161A3 (en) Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride, process for their preparation and pharmaceutical compositions containing the crystalline forms
CA2275596A1 (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
RU99115083A (ru) 1-фенилалкил-1,2,3,6-тетрагидропиридины для лечения болезни альцгеймера
NZ217818A (en) Substituted piperidine butanamide, n-oxides derivatives and pharmaceutical compositions
MY126298A (en) Microparticulate form of a tetrahydropyridine derivative
BRPI0410934A (pt) método para a produção de chocolate, e, chocolate
UA85556C2 (ru) Способ получения шоколада путем добавления к шоколадной массе диглицеридного эфира лимонной кислоты и композиция шоколада, полученного указанным способом
IL154302A0 (en) Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine